Shares of Novocure (NVCR) are up over 28% at $22 in premarket trading, following positive regulatory news related to Optune Lua, a wearable cancer therapy system that delivers Tumor Treating Fields, or TTFields, therapy.
Optune Lua has received FDA approval for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.